PERFORMACIDE® meets the Center for Disease Control and Prevention recommendations for the Environmental Control of Candida auris

Tuesday, December 6, 2016

FORT LAUDERDALE, Fla., Dec. 6, 2016 /PRNewswire/ — Ocean Bio-Chem, Inc. (OBCI) announced today the Center for Disease Control and Prevention (CDC) recently announced that drug resistant Candida auris infections have been identified in hospitals in the United States.  The CDC report went on to state that C. auris infections tends to occur in hospitalized patients and can be resistant to antifungal drugs. In the announcement, the CDC recommended thorough daily and after-discharge cleaning of rooms of C. auris patients using EPA registered hospital disinfectants active against fungi.

In addition to the CDC recommendations, on November 28th, the EPA which is responsible for regulating hospital disinfectants and other antimicrobial pesticides used in healthcare facilities issued recommendations for using hospital disinfectant products with fungal claims, which should be effective against C. auris.  PERFORMACIDE® Hard Surface Disinfectant (EPA Registration. No. 87508-3) is a hospital grade Disinfectant/Fungicide/Tuberculocide/Virucide that meets these recommendations.

PERFORMACIDE® uses a liquid chlorine dioxide solution that can be easily prepared by combining tap water and a patented pouch system in a ready to use trigger spray bottle.  Because the activated solution does not leave harmful residues, rinsing of treated surfaces is not required once the product has been allowed to air dry.  Ocean Bio-Chem is currently shipping PERFORMACIDE® through online retailers as well as distributors.

Peter Dornau went on to say “With the many drug resistant outbreaks becoming more commonplace, it is critical that hospitals and health care facilities review their standard operating practices to include PERFORMACIDE® and prevent future outbreaks.”

About Ocean Bio-Chem, Inc.:

Ocean Bio-Chem, Inc. manufactures, markets and distributes a broad line of appearance and maintenance products for the marine, automotive, power sports, recreational vehicle and outdoor power equipment markets under the Star brite®, Star Tron®, Odor Star®, Outdoor Collection and other brand names within the United States of America and Canada. In addition, the Company produces private label formulations of many of its products for various customers and provides custom blending and packaging services for these and other products. The Company also manufactures, markets and distributes a line of disinfectant, sanitizing and deodorizing products under the Star brite® and Performacide® brand names.

The Company trades publicly under NASDAQ Capital Markets, Ticker Symbol: OBCI.

The Company’s web sites are:

Forward-looking Statements:

Certain statements contained in this Press Release, including without limitation, our ability to market and sell Performacide®in the hospital and health care sectors constitute forward-looking statements. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “believe,” “may,” “will,” “expect,” “anticipate,” “intend,” or “could,” including the negative or other variations thereof or comparable terminology, are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from those expressed or implied by such forward-looking statements. Factors that may affect these results include, but are not limited to, the highly competitive nature of our industry; reliance on certain key customers; changes in consumer demand for marine, recreational vehicle and automotive products; advertising and promotional efforts; unanticipated litigation developments; exposure to market risks relating to changes in interest rates, foreign exchange rates, prices for raw materials that are petroleum or chemical based and other factors addressed in Part I, Item 1A (“Risk Factors”) in our annual report on Form 10-K for the year ended December 31, 2015.